Clinical Feasibility of Nab-paclitaxel Plus Gemcitabine-cisplatin Chemotherapy in Locally Advanced Cholangiocarcinoma

The objective of this observational study is to identify patients with locally advanced cholangiocarcinoma treated with nab-paclitaxel and gemcitabine-cisplatin chemotherapy.In this clinical study, peripheral blood and tumor tissues will be analyzed at baseline and every 3 cycles after systemic drug treatment in patients with locally advanced cholangiocarcinoma, and correlation with treatment was analyzed. This is an exploratory study to discover biomarkers that are highly correlated with treatment response.

Inclusion Criteria:Those above the age of 19 who understand the purpose of the study and agree to participate in the collection of samples during the study.Patients with histologically or cytologically confirmed inoperable locally advanced cholangiocarcinoma (gallbladder cancer, extrahepatic biliary tract cancer, intrahepatic biliary tract cancer)Patients who underwent an NGS test with advanced cholangiocarcinoma tissuesPatients planning to be treated with nab-paclitaxel plus gemcitabine-cisplatin combination therapyECOG performance status 0 or 1Exclusion Criteria:Systemic condition accompanied by instability of vital signs such as infection or organ failurePatients who have previously received palliative chemotherapy for cholangiocarcinomaThose with mental/neurological conditions or dementia who have difficulties understanding and completing the consent formThose who are assessed as not suitable for this study, at the discretion of the researcher